Since the establishment in 2005, China Financial Strategy Investment Holdings Group ("CFS") has focused on equity investment and financing consulting services with its own funds and managed funds, and is committed to promoting technological innovation and industrial upgrading of global and Chinese high-growth industries and enterprises.
Headquartered in Hong Kong, the group company has Type 4 Advising on securities and Type 9 Asset management licenses license from the Hong Kong Securities Regulatory Commission and registered as a qualified private equity Fund Manager with the Asset Management Association of China.
We provide enterprises with financial investment and strategic consulting that are consistent with their own development characteristics, and provide enterprises with long-term and sustainable support services. Help customers deal with practical problems in operations from a strategic perspective, grasp the development trends and best investment opportunities in target industries, and avoid development risks.
We brings together dozens of senior investment and industry experts located in Hong Kong, Beijing, Shanghai and Shenzhen, with rich industry experience and practical results.
佰君生物由行业资深CRO专家创立，专注于为全球制药及生物科技企业提供一站式临床前药物发现解决方案，涵盖从靶点验证到GLP毒理的全方位研发服务。
Founded by industry veterans, Biometas provides integrated preclinical drug discovery solutions, offering comprehensive R&D services from target validation to GLP toxicology for pharmaceutical and biotech companies worldwide.
上海睿智化学研究有限公司成立于2003年，是睿智医药旗下的核心CRO/CDMO品牌，可提供覆盖药物化学、生物分析、药理药效、药代毒理及工艺研发的“一站式”新药研发服务。
Established in 2003 as a core CRO/CDMO brand under ChemPartner, Shanghai ChemPartner offers integrated drug R&D services spanning medicinal chemistry, bioanalysis, pharmacology, DMPK, toxicology, and process development.
（01873.HK）成立于2008年，是全球领先的基于结构的药物发现服务商，向全球生物科技及制药客户提供从早期药物发现到商业化交付的一站式综合服务，并以独特的服务换股权模式深度赋能创新药企。
Founded in 2008 and listed on HKEX (01873.HK), Viva Biotech is a global leader in structure-based drug discovery, providing integrated services from early-stage research to commercial delivery, while empowering biotech innovators through its unique “service-for-equity” model.
（02228.HK）是一家以量子物理、人工智能和机器人自动化驱动的创新平台型科技公司，为全球制药及材料科学产业提供智能化药物与材料研发解决方案。
XtalPi (02228.HK) is an innovative platform company driven by quantum physics, AI, and robotic automation, delivering intelligent R&D solutions for the global pharmaceutical
公司成立于2021年，专注于细胞技术与干细胞技术开发，涵盖免疫细胞、干细胞、外泌体、医疗器械等产品的研发与生产，并推动相关科技成果转化。
Founded in 2021, specializes in cell and stem cell technology development, covering R&D and production of immune cells, stem cells, exosomes, and medical devices, while advancing the translation of scientific achievements.
（1244.HK）是一家进入商业化阶段的肿瘤创新药公司，专注于肿瘤慢病化治疗领域，自主研发了全球首个皮下注射PD-L1抗体恩沃利单抗，致力于帮助肿瘤患者活得更久更好。
3D Medicines (1244.HK) is a commercial-stage oncology innovator focused on chronic disease management for cancer, having developed the world‘s first subcutaneously injected PD-L1 antibody envafolimab, dedicated to helping cancer patients live longer and better.
成立于2016年，是一家临床阶段的眼科创新药研发公司，专注于治疗干眼症、青光眼等眼科疾病的新药研发，致力于为全球眼科疾病患者提供更优的治疗选择。
Founded in 2016, VivaVision Bio is a clinical-stage biotech company dedicated to developing innovative therapies for ophthalmic diseases including dry eye disease and glaucoma, striving to provide better treatment options for patients worldwide.
一家专注于全球领先的小分子抗肿瘤新药开发的生物科技公司，致力于突破癌症中重要的“难以成药”靶点，聚焦原始创新，为癌症患者提供更多更好的用药选择。
GenHouse Bio is a biotechnology company focused on the development of world-class small-molecule oncology drugs, committed to tackling important “undruggable” targets in cancer and delivering more and better treatment options for cancer patients.
于2018年在美国圣地亚哥成立，是一家临床阶段的生物技术公司，专注于开发新一代URAT1抑制剂，用于降低血清尿酸水平、减少痛风发作并溶解痛风石。
Founded in 2018 in San Diego, California, Arthrosi Therapeutics is a clinical-stage biotech company focused on developing next-generation URAT1 inhibitors to lower serum urate levels, reduce gout flares, and dissolve tophi.
2015年从新加坡科技研究局孵化而出，专注于开发First-in-class的TCR-T细胞疗法，用于治疗病毒相关癌症及慢性感染，其HBV特异性TCR-T疗法已在肝细胞癌患者中展现出良好安全性及显著疗效。
Spin off from A*STAR Singapore in 2015, Lion TCR is dedicated to developing first-in-class TCR-T cell therapies for virus-related cancers and chronic infections, with its HBV-specific TCR-T therapy demonstrating favorable safety and significant efficacy in hepatocellular carcinoma patients.
国际化生物技术公司，专注于利用TCR-T 细胞疗法治疗病毒感染及相关癌症。
An international biotech company focused on using TCR-T cell therapy to treat viral infections and related cancers.
是一家AI驱动的临床阶段创新药物研发公司，拥有一站式AI药物发现平台Molecule Pro，聚焦于创新型及难成药靶点的新药研发，致力于持续输出兼具差异化和高临床价值的候选药物。
MindRank is a clinical-stage AI-driven drug discovery company powered by its proprietary one-stop AI platform Molecule Pro, focused on innovative and difficult-to-drug targets, committed to continuously delivering differentiated drug candidates with high clinical value.
一家聚焦于生物技术领域的技术开发与服务的创新型企业，致力于通过微生物组等前沿技术探索慢性疾病的全新治疗方案。
Proviva (Bozhi Bio) is an innovative biotech company focusing on technology development and services in the biotechnology field, exploring novel therapeutic approaches for chronic diseases through cutting-edge microbiome technologies.
一家专注于医药技术研发与服务的创新企业，依托先进的生物技术平台，致力于为制药行业提供高质量的技术解决方案
an innovative enterprise dedicated to pharmaceutical technology R&D and services, leveraging advanced biotechnology platforms to deliver high-quality technical solutions for the pharmaceutical industry.
一家专注于小分子创新药物研发的生物科技公司，聚焦自身免疫疾病及慢性伤口愈合领域的差异化新药开发，旨在满足未被满足的巨大临床需求。
a biotech company focused on small-molecule innovative drug development, specializing in differentiated new drugs for autoimmune diseases and chronic wound healing to address significant unmet clinical needs.
一家专注于研发双抗ADC药物的生物科技公司，聚焦肿瘤字面领域的创新药物开发。
A biotech company focused on the R&D of bispecific antibody-drug conjugates (ADCs), concentrating on innovative drug development in the oncology field.
是一家中美合资的抗癌新药研发公司，专注于通过全球领先的靶向蛋白降解平台，开发针对“不可成药”靶点的创新药物，致力于克服肿瘤治疗中的耐药问题。
Innovo is a Sino-US joint venture oncology drug discovery company focused on developing innovative drugs against “undruggable” targets through its leading targeted protein degradation platform, addressing drug resistance challenges in cancer therapy.
成立于2017年，是一家专注于创新大分子生物药研发的公司，致力于针对难治性癌症、自身免疫性疾病和代谢疾病开发治疗性生物新药，拥有双特异性抗体、T细胞衔接器等自主技术平台。
Founded in 2017, QureBio is focused on the R&D of innovative biologic drugs, dedicated to developing novel therapies for refractory cancers, autoimmune diseases, and metabolic disorders, with proprietary platforms including bispecific antibodies and T cell engagers.
一家临床阶段生物医药公司，旨在开发下一代口服底物减少疗法 (SRT)，以解决未满足的重大医疗需求并改善患有遗传性鞘糖脂代谢疾病患者的生活质量。
A clinical-stage biopharmaceutical company aiming to develop next-generation oral substrate reduction therapies (SRT) to address significant unmet medical needs and improve the quality of life for patients with inherited disorders of glycosphingolipid metabolism.
一家植根中美两地的生物科技公司，利用独特的IDInVivo⁺平台（结合遗传学与人工智能技术），在免疫功能完整的活体动物中直接发现新药靶点，致力于开发乙肝、癌症和自身免疫性疾病的First-in-class疗法。
Drug Farm is a US-China biotech company leveraging its proprietary IDInVivo⁺ platform—which integrates genetics and AI—to directly identify novel drug targets in immune-intact living animals, focused on developing first-in-class therapies for hepatitis B, cancer, and autoimmune diseases.
迈英诺医药旗下的子公司，专注于创新型医药产品的研发，核心产品MDI-1228系列药物已在美国获批开展糖尿病足临床研究。
It is focused on innovative pharmaceutical product R&D, with its core MDI-1228 series having received approval for diabetic foot clinical studies in the US.
一家代谢类疾病创新药研发平台，除血脂异常外，公司在疼痛、心脑血管等多个慢性疾病领域均有布局，这些领域存在大量未被满足的医疗需求。
A metabolic disease innovative drug R&D platform. In addition to dyslipidemia, the company has a presence in multiple chronic disease areas such as pain, cardiovascular and cerebrovascular diseases, where there are significant unmet medical needs.
以能源服务和高科技产业为主的多元化集团公司，主营业务涵盖工程服务、海洋工程、清洁能源及化工新材料，全球化布局覆盖东南亚、中东、非洲、美洲及欧洲等地。
Wison Group is a diversified conglomerate focused on energy services and high-tech industries, with core businesses spanning engineering services, offshore engineering, clean energy, and advanced chemical materials, operating globally across Southeast Asia, the Middle East, Africa, the Americas, and Europe.
（002212.SZ），面向基础网络、工业互联网、物联网、车联网等全业务场景提供全面的网络安全与智算云解决方案。
providing comprehensive cybersecurity and intelligent cloud solutions across foundational networks, industrial internet, IoT, and connected vehicles.
是一家集汽车发动机零部件研发、生产、销售为一体的高新技术企业，主要产品包括缸体、缸盖、连杆、飞轮壳等发动机核心零部件。
a high-tech enterprise integrating R&D, production, and sales of automotive engine components, with core products including cylinder blocks, cylinder heads, connecting rods, and flywheel housings.
一家专注于大型车辆辅助制动技术的高科技创新型企业，拥有多项国内外核心发明专利，主要产品为第三代苍泰水介质液力缓速器。
a high-tech innovation enterprise focused on auxiliary braking technology for large vehicles, holding multiple core patents in China and internationally, with its flagship product being the third-generation Cangtai water-medium hydraulic retarder.
是中国领先的儿童消费品开发商及经销商，旗下拥有博士蛙、Baby2、Dr. Frog等自有品牌及哈利波特、NBA等多个知名授权品牌。
a leading developer and distributor of children‘s consumer products in China, operating proprietary brands including Boshiwa, Baby2, and Dr. Frog, along with several licensed brands including Harry Potter and NBA.
成立于2003年，是中国最大的民营环氧乙烷及AEO表面活性剂生产商和供应商，主要从事环氧乙烷、乙二醇、聚丙烯及表面活性剂的生产与供应。
Founded in 2003 and listed on HKEX (02198.HK), China Sanjiang Fine Chemicals is the largest private producer and supplier of ethylene oxide (EO) and AEO surfactants in China, primarily engaged in the production and supply of EO, ethylene glycol, polypropylene, and surfactants.
致力于多晶硅材料的研发、生产和销售，是光伏能源产业链上游重要的硅材料供应商，秉承“把绿色能源带进生活”的理念，推动新能源产业发展。
GCL Silicon Industry is dedicated to the R&D, production, and sale of polysilicon materials, serving as a key upstream silicon material supplier in the photovoltaic energy industry chain, committed to “bringing green energy into life” and advancing the new energy industry.
主要从事高性能膜材料等高分子新材料的研发与生产，产品广泛应用于电子、建筑、汽车等高端制造领域。
Founded in 2018, Nanjing Qingyan Polymer New Materials Co., Ltd. is primarily engaged in the R&D and production of high-performance membrane materials and other advanced polymer materials, with products widely used in electronics, construction, automotive, and other high-end manufacturing sectors.
一家供排水一体化、具有完整水务产业链的国有控股水务公司，主要从事自来水生产供应及污水处理业务。
a state-controlled water utility company with an integrated water supply and drainage system and a complete water industry chain, primarily engaged in tap water production and supply as well as wastewater treatment services.
为多个航空航天领域的企业或研究院所提供技术研发和试验检测服务的企业，承担着我国多种武器装备用特种陶瓷基复合材料构件的研制任务。
A company that provides technical R&D and testing services to multiple enterprises and research institutes in the aerospace sector, undertaking the development of special ceramic matrix composite components for various types of weapons and equipment used in China.
Mr. Hua is the chairman of China Financial Strategy Investment Holdings Group, and has served as CEO of ChemPartner (SZ.300149) and co-founder & CFO of Viva Biotech (HK.01873);
Served as head of the International Direct Investment Department and Investment Banking Department of Bank of Communications;
In the past 20 years, he has also served as the director of many large international banks, completed a total of 200 listing and refinancing projects and 50 financial advisory projects, and led investments in more than 100 companies, with a total cumulative amount of more than 100 billion US dollars. Nearly half of the investment projects were in the life and health field, and he has rich industrial experience and resources;
Currently, Mr. Hua also serves as a director of listed biopharmaceutical companies such as Lepu Biopharma (HK.2157) and Biocytogen (HK.2315). Mr. Hua holds an EMBA degree from Yale University and a master's degree in business administration from Japan International University.
Mr. Cao is a founding partner of China Financial Strategy Investment Holdings Group.
Mr. Cao assisted in the establishment of the Shanghai office of BoCom International and the establishment of the BoCom International Equity Investment Fund, with a total management capital of approximately US$50 million. He is a member of the fund investment committee and a core figure in many investments.
He once served as the investment manager of Shanghai Shenya Investment Co., Ltd. and participated in a series of investments including the restructuring and privatization of state-owned enterprises such as Nanning Water Affairs. Prior to this, Mr. Cao was the deputy general manager of Shanghai Ruiying Investment, a subsidiary of Shenzhen Venture Capital Group, and participated in many mergers and acquisitions transactions, including Weichai Power’s 1.023 billion yuan subscription for Hunan Torch.
He once worked for venture capital institutions such as China Southern Capital and Risheng Hong Kong Jiafu and participated in many IPO and M&A projects.
Holds a master's degree in international development from Japan International University and a bachelor's degree in economics from Hangzhou University.
Ms. Lin is a Partner at China Financial Strategy and Chair of Asia Regio
She has over 25 years of experience in investment banking and equity capital markets, having served as Head of Equity Capital Markets at Vantage Capital Markets, BOCI, BOCOM International, and Daiwa Capital
Leading the completion of pre-IPO financing, IPO, placement and other equity-related financing transactions for 100+ companies listed on stock exchanges in Hong Kong, the United States, Singapore, London, Saudi Arabia and Germany
Proficient in providing credit and equity financing solutions to listed and unlisted companies, and good at exploring cross-border M&A opportunities for enterprises and major shareholders to create value. Business coverage includes China, Hong Kong, and Southeast Asia.
Mr. Jin has nearly 20 years of experience in domestic and overseas investment, mergers and acquisitions and fund management of large state-owned enterprises and private enterprises. He has been engaged in domestic and overseas equity investment and fund management in SDIC Hi-Tech, State Nuclear Power Investment and Dongxu Group. The fund company he worked for has achieved a cumulative fund management scale of nearly 3 billion yuan.
He is good at overseas investment and mergers and acquisitions, and has led the completion of overseas project investments or acquisitions in Australia, Myanmar, Indonesia, etc.
He holds an MBA from the Business School of the University of Birmingham, UK, and a bachelor's degree in Electronic Engineering from Shandong University.
Mr. Tao is the strategic investment director of China Financial Strategy and the vice president of BioMetas. He has served as the assistant chief financial officer and deputy director of strategic planning of Viva Biotech and the vice president of strategic development of ChemPartner.
Responsible for corporate finance and strategic management, including pre-IPO financing, IPO, convertible bond issuance and placement and other refinancing, mergers and acquisitions integration, institutional relations and strategic business cooperation, etc.
He has extensive experience in the fields of PE, VC and FA, and has completed numerous project investments, corporate financing and investment M&A transactions. In the biomedical industry, he participated in and led the establishment, fundraising, investment management and exit of multiple life science comprehensive and special funds.
Holds a master's degree in financial management from University College London and a bachelor's degree in financial management from the University of Sheffield, UK.
Ms. Luo was a former American fund manager and has extensive experience in asset management and fund management operations.
She has extensive experience in global asset allocation and administration, and is good at onshore and offshore fund establishment, financial product research and development, investment portfolio management and monitoring.
She holds a master's degree in economics from the University of Cambridge and the London School of Economics and Political Science, and a bachelor's degree in economics from the University of California, Los Angeles.
Mr. Wu is the Vice President of China Financial Strategy Life and Health Industry Fund
Deputy Director of the Strategic Development Department of BioMetas, formerly the manager of the Strategic Planning Department of Viva Biotech, responsible for industry research, investment and M&A analysis, post-investment management, etc.
Previously worked in the production department of Shanghai Xingjit Biotechnology Co., Ltd., participated in the R&D/production of a variety of third-class biomedical device products for human implantation, and was responsible for process optimization/amplification, quality system establishment, production management, cost control, internal audit, etc.
He holds an EMBA degree from Tongji University and a Bachelor's degree in Medical Device Engineering from the University of Shanghai for Science and Technology.
Mr. Xu is the Vice President of China Financial Strategy Life and Health Industry Fun.
Deputy Director of the Strategic Development Department of BioMetas. He once served as the general manager of the data center and smart city division of CITIC Group and the head of investment and financing of the new infrastructure industry fund. He previously worked for Ferrari Automobile North America, a subsidiary of Fiat, and was responsible for dealer network operation management and financial budget planning, data asset management, supply chain finance, etc.
Holds a bachelor's degree in economics from the University of California, Los Angeles.
